Boston, MA -- (ReleaseWire) -- 05/16/2014 -- Glioblastoma Multiforme (GBM) - Pipeline Review, H1 2014
Global Markets Direct's, 'Glioblastoma Multiforme (GBM) - Pipeline Review, H1 2014', provides an overview of the Glioblastoma Multiforme (GBM)'s therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Glioblastoma Multiforme (GBM), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Glioblastoma Multiforme (GBM) and special features on late-stage and discontinued projects.
View Full Report Details and Table of Contents
Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
- The report provides a snapshot of the global therapeutic landscape of Glioblastoma Multiforme (GBM)
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Glioblastoma Multiforme (GBM) and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Glioblastoma Multiforme (GBM) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
Companies Mentioned in this Report: Johnson & Johnson, F. Hoffmann-La Roche Ltd., Celsion Corporation, Amgen Inc., Sanofi, AstraZeneca PLC, Eli Lilly and Company, GlaxoSmithKline plc, Genentech, Inc., Agenus, Inc., MedImmune, LLC, Dainippon Sumitomo Pharma Co., Ltd., Lentigen Corporation, Sangamo BioSciences, Inc., Plexxikon Inc., Celltrion, Inc., ZIOPHARM Oncology, Inc., Novartis AG, Actelion Ltd, Astellas Pharma Inc., Biocon Limited, Les Laboratoires Servier SAS, Pfizer Inc., Vertex Pharmaceuticals Incorporated, Cell Therapeutics, Inc., Exelixis, Inc., Aduro BioTech, Inc., Celgene Corporation, GW Pharmaceuticals plc, Celldex Therapeutics, Inc., ImmunoCellular Therapeutics, Ltd., Lixte Biotechnology Holdings, Inc., Basilea Pharmaceutica AG, Northwest Biotherapeutics, Inc., Novogen Limited, Oncothyreon Inc., Peregrine Pharmaceuticals, Inc., CytRx Corporation, Prana Biotechnology Limited, Green Cross Cell Corporation, Panacea Biotec Limited, Rexahn Pharmaceuticals, Inc., Nanobiotix SA, Spectrum Pharmaceuticals, Inc., Fusion Antibodies Ltd, Upsher-Smith Laboratories, Inc., Actinium Pharmaceuticals, Inc., Nerviano Medical Sciences S.r.l., Hutchison MediPharma Limited, immatics biotechnologies GmbH, Apogenix GmbH, EnGeneIC Ltd, AGY Therapeutics, Inc., GenSpera, Inc., Diffusion Pharmaceuticals LLC, Orphagen Pharmaceuticals, Inc., Deciphera Pharmaceuticals, LLC, Stemline Therapeutics, Inc., BioCancell Therapeutics, Inc., Axelar AB, Advenchen Laboratories, LLC, VG Life Sciences, Inc., Noxxon Pharma AG, Immunovaccine, Inc., Globeimmune, Inc., InteRNA Technologies B.V., ChemoCentryx, Inc., Xcovery, Inc., TVAX Biomedical, Inc., Biovista Inc., Sirnaomics, Inc., CureTech Ltd., Oncovir, Inc., TRACON Pharmaceuticals, Inc., Nexgenix Pharmaceuticals, LLC, Regulus Therapeutics Inc., Immunomic Therapeutics, Inc., CLL Pharma, DiscoveryBiomed, Inc., Jiangsu Kanion Pharmaceutical Co., Ltd., GreenPeptide Co., Ltd., Incuron, LLC, Terpenoid Therapeutics, Inc., TAU Therapeutics, LLC, EirGen Pharma Ltd., CytoVac A/S, Ampio Pharmaceuticals, Inc., Selvita S.A, Bexion Pharmaceuticals, LLC., Advanced Accelerator Applications, EntreChem, S.L., CureFAKtor Pharmaceuticals. LLC, Oligovax SAS, Ecrins Therapeutics SAS, Sagetis Biotech, S.L., CalAsia Pharmaceuticals, Inc., Activartis Biotech GmbH, CytomX Therapeutics, Inc., Panacela Labs, Inc., Bioncotech Therapeutics S.L., Antoxis Limited, Tolero Pharmaceuticals, Inc., AbbVie Inc., Argon Pharma S.L., AlphaMab Co., Ltd, Galileo Research s.r.l.
About Fast Market Research
Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.
Browse all Pharmaceuticals research reports at Fast Market Research
You may also be interested in these related reports:
- Recurrent Glioblastoma Multiforme (GBM) Global Clinical Trials Review, H1, 2014
- Recurrent Glioblastoma Multiforme (GBM) - Pipeline Review, H2 2013
- Glioblastoma Multiforme (GBM) - Pipeline Review, H2 2013
- Type 1 Diabetes (Juvenile Diabetes) - Pipeline Review, H1 2014
- Metastatic Breast Cancer - Pipeline Review, H1 2014
- Breast Cancer - Pipeline Review, H1 2014
- Multiple Myeloma (Kahler's Disease) - Pipeline Review, H1 2014
- Obesity - Pipeline Review, H1 2014
- Multiple Sclerosis - Pipeline Review, H1 2014
- Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline Review, H1 2014